This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
The company’s main area of focus is cystic fibrosis (CF). The company’s lead marketed products are Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor), Symdeko/Symkevi (tezacaftor in combination with ivacaftor), Orkambi (lumacaftor in combination with ivacaftor) and Kalydeco (ivacaftor), which are collectively approved to treat the majority of the people with CF in North America, Europe and Australia. Trikafta, Vertex’s triple combination regimen, was approved by the FDA in October 2019 for the treatment of CF in people aged 12 years and older who have at least one F508del mutation. Kaftrio (brand name of Trikafta in EU) was approved in the European Union in August 2020. It is also being evaluated in younger patients in the United States. With approval of Trikafta, Vertex can address a significantly larger CF patient population — almost 90% of patients with CF — in the future. Meanwhile, Vertex is pursuing genetic therapies to address the remaining 10% of CF patients. While CF remains the main area of focus, Vertex is also developing treatments for sickle cell disease, thalassemia and pain management.
Biotech Stock Roundup: Regeneron, Celgene, Amgen Impress at ASCO
by Zacks Equity Research
The biotech sector was in focus last week due to the ASCO meet at Chicago where biotech bigwigs presented data on their oncology drugs and promising pipeline candidates.
Zacks Investment Ideas feature highlights: CRISPR, Intellia Therapeutics, Editas and Vertex
by Zacks Equity Research
Zacks Investment Ideas feature highlights: CRISPR, Intellia Therapeutics, Editas and Vertex
Vertex/CRISPR's Sickle Disease Candidate Put on Hold by FDA
by Zacks Equity Research
FDA places clinical hold on a Vertex (VRTX) and CRISPR Therapeutics' IND application for CTX001 for the treatment of sickle cell disease.
Should You Buy the Dip in CRISPR Therapeutics?
by David Borun
A "Clinical Hold" from the FDA has the shares falling, but is it an opportunity to get in?
Vertex Pharmaceuticals (VRTX) Down 1.2% Since Earnings Report: Can It Rebound?
by Zacks Equity Research
Vertex Pharmaceuticals (VRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Is Genome Editing the Next Biotech Breakthrough?
by David Borun
CRISPR technology is promising to be the foundation the treatment of 1000s of diseases
The Zacks Analyst Blog Highlights: General Dynamics, Enbridge, CSX, Humana and Vertex
by Zacks Equity Research
The Zacks Analyst Blog Highlights: General Dynamics, Enbridge, CSX, Humana and Vertex
Top Research Reports for General Dynamics, Enbridge & CSX Corporation
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including General Dynamics (GD), Enbridge (ENB) and CSX Corporation (CSX).
Biotech Stock Roundup: ALXN, VRTX Post Solid Results, GILD Disappoints in Q1
by Zacks Equity Research
The biotech sector was in focus over the last five trading sessions as several bigwigs like Gilead and Vertex, among others reported results while some others provided pipeline updates.
Vertex (VRTX) Q1 Earnings Beat on Strong CF Products Sales
by Zacks Equity Research
Vertex Pharma (VRTX) first-quarter earnings increase from the year-ago period led by strong sales trend of CF drugs.
Is a Beat in Store for Vertex (VRTX) This Earnings Season?
by Zacks Equity Research
Vertex (VRTX) is expected to beat estimates when it reports its Q1 earnings on Apr 26.
Why Earnings Season Could Be Great for Vertex Pharmaceuticals (VRTX)
by Zacks Equity Research
Vertex Pharmaceuticals (VRTX) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.
The Zacks Analyst Blog Highlights: Agios Pharmaceuticals, BioMarin Pharmaceutical, Vertex Pharmaceuticals and Incyte
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Agios Pharmaceuticals, BioMarin Pharmaceutical, Vertex Pharmaceuticals and Incyte
Pharma M&A Active This Week: 4 Potential Buyout Targets
by Indrajit Bandyopadhyay
Novartis and Alexion announce respective acquisitions of AveXis and Wilson Therapeutics for a pipeline boost. We suggest four stocks as hot acquisition picks this year.
Is PowerShares Dynamic Biotechnology & Genome Portfolio (PBE) a Hot ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PBE
Top Research Reports for Oracle, Vale & General Mills
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Oracle (ORCL), Vale (VALE) and General Mills (GIS).
3 Biotech Stocks With Rising Earnings Estimates Post Q4
by Zacks Equity Research
The biotech industry performed reasonably well in Q4. Hence, it is a good idea to select stocks from the sector which saw positive estimate revisions post Q4 earnings release.
Biotech Stock Round Up: Celgene Suffers Setback, Gilead Teams Up with Sangamo
by Zacks Equity Research
The major news in the biotech sector in the last five trading sessions include the FDA's refusal to file letter for Celgene Corporation's (CELG) ozanimod while Gilead Sciences, Inc.'s (GILD) announced an agreement with Sangamo Therapeutics.
The Zacks Analyst Blog Highlights: Amgen, TOTAL, Marriott, PG&E and Vertex
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Amgen, TOTAL, Marriott, PG&E and Vertex
Top Analyst Report for Amgen, TOTAL S.A. & Marriott
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Amgen (AMGN), TOTAL S.A. (TOT) and Marriott (MAR).
Vertex's Third Cystic Fibrosis Treatment Gets FDA Approval
by Zacks Equity Research
Vertex???s (VRTX) FDA approved tezacaftor/ivacaftor combination for cystic fibrosis in patients with certain mutations in the CFTR gene marks the indication???s third treatment.
The Zacks Analyst Blog Highlights: Wells Fargo, Caterpillar, Schlumberger, Vertex and Republic Services
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Wells Fargo, Caterpillar, Schlumberger, Vertex and Republic Services
REGN vs. ALXN: Which Stock is Poised for Better Q4 Earnings?
by Zacks Equity Research
Let's take a look at which of these biotech companies, Alexion (ALXN) or Regeneron (REGN) has an edge ahead of their Q4 release.
Top Stock Reports for Wells Fargo, Caterpillar & Schlumberger
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Wells Fargo (WFC), Caterpillar (CAT) and Schlumberger (SLB).
The Zacks Analyst Blog Highlights: Sanofi, Seattle Genetics, AbbVie, Celgene and Vertex
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Sanofi, Seattle Genetics, AbbVie, Celgene and Vertex